Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523858 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
A Phase 3 study of Progressive Multiple Sclerosis (PMS), sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 927
- Enrollment target
- 20
- Study locations
NCT03523858 is a Phase 3 study of Progressive Multiple Sclerosis (PMS) that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 927 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03523858, a Phase 3 study of Progressive Multiple Sclerosis (PMS), is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 927 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Conditions Studied
Interventions
- DRUG Ocrelizumab
Study Locations (20)
California
- MS Center of California - Laguna Hills
- SC3 Research Group, Inc - Pasadena
- University of California San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dragonfly Research, LLC - Wellesley
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic Mellen Center - Cleveland
Texas
- Central Texas Neurology Consultants - Round Rock
- Lone Star Neurology of San Antonio - San Antonio
Other
- University Clinical Center of the Republic of Srpska - Banja Luka
- University Hospital Mostar - Mostar
Connecticut
- Yale University - North Haven
Florida
- University of South Florida - Tampa
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2018-05-28 |
| Est. Completion | 2026-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523858
The ClinicalTrials.gov registry entry for NCT03523858 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 927 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Multiple Sclerosis (PMS) appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT03523858 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT03523858 about?
NCT03523858 is a clinical study titled "A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis". This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
What is the current status of trial NCT03523858?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 927 participants. The study started on 2018-05-28. Estimated completion is 2026-11-12.
What conditions does trial NCT03523858 study?
This clinical trial studies the following conditions: Progressive Multiple Sclerosis (PMS).
What interventions are being tested in trial NCT03523858?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03523858?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03523858 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.